Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer

作者: Fariz Nurwidya , Fumiyuki Takahashi , Akiko Murakami , Kazuhisa Takahashi

DOI: 10.3969/J.ISSN.2095-3941.2012.01.003

关键词:

摘要: One of the most important pathways in non-small cell lung cancer (NSCLC) is epidermal growth factor receptor (EGFR) pathway. This pathway affects several crucial processes tumor development and progression, including proliferation, apoptosis regulation, angiogenesis, metastatic invasion. Targeting EGFR currently being intensely explored. We are witnessing a number potential molecular-inhibiting treatments for application clinical oncology. In last decade, tyrosine kinase (TK) domain was identified NSCLC patients, it has responded very well with dramatic improvement to TK inhibitors such gefitinib erlotinib. Unfortunately, there were primary and/or secondary resistance these treatments, as shown by trials. Subsequent molecular biology studies provided some explanations drug phenomenon. The mechanisms need be clarified. An in-depth understanding targeted-therapy may help us explore new strategies overcoming or reversing future treatment.

参考文章(35)
Andreas Gschwind, Oliver M. Fischer, Axel Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer. ,vol. 4, pp. 361- 370 ,(2004) , 10.1038/NRC1360
Bruce E. Johnson, Pasi A. Jänne, Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer Cancer Research. ,vol. 65, pp. 7525- 7529 ,(2005) , 10.1158/0008-5472.CAN-05-1257
Takafumi Kubo, Hiromasa Yamamoto, William W. Lockwood, Ilse Valencia, Junichi Soh, Michael Peyton, Masaru Jida, Hiroki Otani, Tetsuya Fujii, Mamoru Ouchida, Nagio Takigawa, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, John D. Minna, Marileila Varella-Garcia, Wan L. Lam, Adi F. Gazdar, Shinichi Toyooka, MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer. ,vol. 124, pp. 1778- 1784 ,(2009) , 10.1002/IJC.24150
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne, Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Cancer Cell. ,vol. 17, pp. 77- 88 ,(2010) , 10.1016/J.CCR.2009.11.022
Lionel M.L. Chow, Suzanne J. Baker, PTEN function in normal and neoplastic growth Cancer Letters. ,vol. 241, pp. 184- 196 ,(2006) , 10.1016/J.CANLET.2005.11.042
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
P. S. Hammerman, P. A. Janne, B. E. Johnson, Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 15, pp. 7502- 7509 ,(2009) , 10.1158/1078-0432.CCR-09-0189
Hideki Endoh, Yasushi Yatabe, Takayuki Kosaka, Hiroyuki Kuwano, Tetsuya Mitsudomi, PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Journal of Thoracic Oncology. ,vol. 1, pp. 629- 634 ,(2006) , 10.1016/S1556-0864(15)30374-9
Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, Mark A. Lemmon, ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 7692- 7697 ,(2010) , 10.1073/PNAS.1002753107